Advertisement

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Deborah Collyar: What's In It for Patients?

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement

Jul

17

Today In Oncology

Meta-Analysis Highlights Cardiovascular Safety Advantage of Second-Generation BTK Inhibitors

ctDNA Status May Predict Benefit From Adjuvant Chemotherapy After Resection of Colorectal Liver Metastases

Tumor Microenvironment Ecotypes May Explain Differences in Multiple Myeloma Outcomes

Expert Dermatologists Outperform AI Foundation Models in Real-World Skin Cancer Diagnosis

Node-Negative Breast Cancer 20-Year Outcomes With IM-MS Lymph Node Irradiation

Advertisement

© 2026 HSP News Service, L.L.C.